ripa-56

RIPA-56 is a **potent and selective small molecule inhibitor** of **receptor-interacting protein kinase 1 (RIPK1)**, with an IC₅₀ of 13 nM, showing high metabolic stability and oral bioavailability. By targeting RIPK1, it blocks necroptosis—a form of programmed cell death—as well as inflammation, apoptosis, and ferroptosis. RIPA-56 demonstrates protective effects in preclinical models of systemic inflammatory response syndrome, multiple sclerosis, non-alcoholic steatohepatitis, retinal injury/glaucoma, and organ damage conditions by inhibiting RIPK1-driven nocroptotic and inflammatory responses. It does not inhibit RIPK3 kinase at tested concentrations, and also impacts pathways involving MLKL, Caspase-3, BAX, Bcl-2, and Gpx4. RIPA-56 was developed following high-throughput screening and structure optimization, and is chiefly a research tool, not yet approved for human therapeutic use[1][2][3][4][5][7][9].

Other names

N-Benzyl-N-hydroxy-2,2-dimethylbutanamideRIPA 56RIPA56RIPA-56